(224 days)
No
The device description and performance studies focus on the mechanical properties and design of a spinal implant, with no mention of AI or ML capabilities.
Yes
The device is intended to stabilize the spinal segment to promote fusion as a treatment for degenerative disc disease.
No
The Cogent Med-LIF is an interbody fusion device intended to stabilize the spinal segment and promote fusion, which is a therapeutic function, not a diagnostic one. Its purpose is to treat degenerative disc disease by facilitating fusion, not to identify or characterize the disease itself.
No
The device description clearly states it consists of physical components made of PEEK and titanium, which are hardware.
Based on the provided information, the Cogent Med-LIF is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, or tissue) to provide information for diagnosis, monitoring, or screening.
- Cogent Med-LIF Function: The Cogent Med-LIF is an implantable device designed to be surgically placed in the lumbar spine to promote intervertebral body fusion. It is a physical device used within the body, not for testing samples outside the body.
- Intended Use: The intended use clearly states it's for use with autogenous bone graft in patients with degenerative disc disease for intervertebral body fusion. This is a therapeutic and structural function, not a diagnostic one.
- Device Description: The description details the physical components of the implant (PEEK spacers, titanium linkage, etc.) and its purpose in stabilizing the spinal segment.
Therefore, the Cogent Med-LIF falls under the category of a medical device, specifically an implantable spinal fusion device, rather than an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Cogent Med-LIF is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These devices are intended for intervertebral body fusion, and are intended to be used with supplemental fixation instrumentation which has been cleared by the FDA for use in the lumbar spine.
Product codes
MAX
Device Description
The Cogent Med-LIF is an interbody fusion device intended to stabilize the spinal segment to promote fusion. The Cogent Med-LIF consists of two PEEK spacers with axial voids to contain bone graft material, a titanium linkage that connects the PEEK spacers, angular anti-migration teeth, and tantalum x-ray markers.
The Cogent Med-LIF is available in various sizes to accommodate varying patient anatomy. The implants come in two lordotic options, 0° (parallel) and 6° (lordotic). The parallel implants are available in heights ranging from 8mm to 16mm and the lordotic implants are available in heights ranging from 10mm to 16mm. All implants are 10mm wide and are available in three lengths; 20, 25 and 30mm.
The Cogent Med-LIF implants may be inserted via an open or minimally invasive approach and may be placed as a single implant or as two units bilaterally in the same intervertebral space.
The Cogent Med-LIF implants are non-sterile and are to be sterilized by the end user.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Spinal segment, L2 to S1
Indicated Patient Age Range
Skeletally mature
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Cogent Spine conducted the following bench tests:
ASTM F2077
- Static Axial Compression
- Dynamic Axial Compression
- Static Shear Compression
- Dynamic Shear Compression
ASTM F2267
- Subsidence
Expulsion Testing per ASTM Draft Standard F04.25.02.02
Additionally, Cogent Spine conducted a cadaveric implantation study to confirm autogenous bone graft can be adequately delivered when compared to a legally marketed predicate.
In summary, mechanical and non-clinical testing of the Cogent Med-LIF device indicated no new risks and demonstrated substantial equivalence in performance compared to a legally marketed predicate.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
K113478, K073470, K090566, K121693
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3080 Intervertebral body fusion device.
(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
0
APR 1 5 2014
SUBMITTER:
Submitted Bv:
| Company Name: | Cogent Spine |
|---|---|
| Address: | 101 N. Acacia, Suite 106 |
| Solana Beach, CA 92075 | |
| Telephone: | (858) 774-7891 |
CONTACT PERSON: Jude Paganelli
DATE PREPARED: April 15, 2014
TRADE NAME: Cogent Med-LIF
COMMON NAME: Intervertebral Body Fusion Device
CLASSIFICATION NAME: Intervertebral Body Fusion Device (21 CFR 888.3080)
PRODUCT CODE: MAX
SUBSTANTIALLY EQUIVALENT TO:
The Cogent Med-LIF is substantially equivalent to the predicates in all facets including: indications, technology, method of use and performance. The predicate devices for the Cogent Med-LIF system are:
Eisertech PLIF Cage (K113478) Stryker Spine AVS PL PEEK Spacers (K073470) Custom Spine Pathway Avid (K090566) Sapphire Medical Group A-Wedge Anterior Interbody System (K121693)
DESCRIPTION of the DEVICE:
The Cogent Med-LIF is an interbody fusion device intended to stabilize the spinal segment to promote fusion. The Cogent Med-LIF consists of two PEEK spacers with axial voids to contain bone graft material, a titanium linkage that connects the PEEK spacers, angular anti-migration teeth, and tantalum x-ray markers.
The Cogent Med-LIF is available in various sizes to accommodate varying patient anatomy. The implants come in two lordotic options, 0° (parallel)
510(K) Submission:
1
510(k) Summary-Continued
and 6° (lordotic). The parallel implants are available in heights ranging from 8mm to 16mm and the lordotic implants are available in heights ranging from 10mm to 16mm. All implants are 10mm wide and are available in three lengths; 20, 25 and 30mm.
The Cogent Med-LIF implants may be inserted via an open or minimally invasive approach and may be placed as a single implant or as two units bilaterally in the same intervertebral space.
The Cogent Med-LIF implants are non-sterile and are to be sterilized by the end user.
MATERIALS:
The Cogent Med-LIF is manufactured from polyetheretherketone (PEEK) as per ASTM F2026 and contains titanium alloy (Ti-6Al-4V) per ASTM F1472 and tantalum per ASTM F560.
INDICATIONS FOR USE:
The Cogent Med-LIF is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These devices are intended for intervertebral body fusion, and are intended to be used with supplemental fixation instrumentation which has been cleared by the FDA for use in the lumbar spine.
PERFORMANCE TESTING:
Cogent Spine conducted the following bench tests:
ASTM F2077
- . Static Axial Compression
- Dynamic Axial Compression ●
- Static Shear Compression .
- Dynamic Shear Compression .
ASTM F2267
· Subsidence
Expulsion Testing per ASTM Draft Standard F04.25.02.02
2
510(k) Summary-Continued
Additionally, Cogent Spine conducted a cadaveric implantation study to confirm autogenous bone graft can be adequately delivered when compared to a legally marketed predicate.
In summary, mechanical and non-clinical testing of the Cogent Med-LIF device indicated no new risks and demonstrated substantial equivalence in performance compared to a legally marketed predicate.
CONCLUSIONS:
The Cogent Med-LIF device has shown to be substantially equivalent to legally marketed predicates based on indications for use, technological characteristics, performance testing and comparison to predicate devices.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
April 15, 2014
Cogent Spine LLC % Mr. Jude Paganelli Cor Medical Ventures LLC 101 North Acacia Avenue, Suite 106 Solana Beach, California 92075
Re: K132738
Trade/Device Name: Cogent Med-LIF Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX Dated: February 12, 2013 Received: March 21, 2014
Dear Mr. Paganelli:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must or any I vith all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical CI K Fall 607); adoling (21 OFF 803); good manufacturing practice requirements as set
4
Page 2 - Mr. Jude Paganelli
forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the clectronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers. International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours.
Ronald P. Jean -S for
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.
510(k) Number (if known) K132738
Device Name Cogent Med-LIF
Indications for Use (Describe)
The Cogent Med-LIF is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These devices are intenertebral body fusion, and are intended to be used with supplemental fixation instrumentation which has been cleared by the FDA for use in the lumbar spine.
Type of Use (Select one or both, as applicable)
2 Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
Anton E. Dmitriev, PhD
.
Division of Orthopedic Devices
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."